The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Exelixis; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Pfizer
David J Figueroa
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Yuan Liu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Robert C. Gagnon
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Keith C. Deen
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Christopher Carpenter
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Arundathy N. Bartlett-Pandite
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Paul De Souza
Consultant or Advisory Role - GlaxoSmithKline
Tom Powles
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Novartis; Pfizer
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Pfizer